PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ccmbmLink to Publisher's site
 
Clin Cases Miner Bone Metab. 2017 May-Aug; 14(2): 254–257.
Published online 2017 October 25. doi:  10.11138/ccmbm/2017.14.2.254
PMCID: PMC5726222

Multiple fractures and impaired bone metabolism in Wolfram syndrome: a case report

Summary

Wolfram Syndrome (WS) is a rare and lethal disease characterized by optic atrophy, diabetes mellitus, diabetes insipidus, and hearing loss. To date, osteoporotic related fractures have not been reported in affected patients. Here, we describe the case of a man affected by WS complicated by several bone fragility fractures.

A 50-year-old Caucasian man was hospitalized because of tibia and fibula fractures. His clinical features included diabetes mellitus, diabetes insipidus, optic atrophy and deafness that were consistent with an unrecognized WS diagnosis, which was confirmed by the identification of a specific mutation in gene WFS1 encoding wolframin. Bone mineral density by phalangeal quantitative ultrasound demonstrated severe osteoporosis, with high serum levels of surrogate markers of bone turn-over. Previously unidentified rib fractures were also detected.

To the best of our knowledge, this is the first report of osteoporotic related fractures in a patient affected by WS. Although no effective treatments are currently available to delay the progression of the disease, this case report suggests to evaluate fracture risk in the diagnostic work-up of WS.

Keywords: Wolfram syndrome, diabetes, bone, osteoporosis, fractures

Introduction

Wolfram syndrome (WS) is a rare autosomal recessive genetic disorder. It is also known as DIDMOAD syndrome, an acronym for diabetes insipidus (DI), diabetes mellitus (DM), optic atrophy (OA), and sensorineural deafness (D) (1). Wolfram and Wagener, who found four of eight siblings with juvenile diabetes mellitus and optic nerve atrophy, first described the syndrome in 1938 (2).

The diagnosis is delayed by the progressive occurrence of the different clinical features over time, with most of WS patients presenting with non-immune, insulin-deficient diabetes mellitus followed by optic atrophy in the first decade, central diabetes insipidus and sensorineural deafness in the second decade, dilated renal outflow tracts in the third decade, and multiple neurological abnormalities early in the fourth decade (1, 3). Although there have been over 200 WS cases reported to date, the prognosis is still fatal, as most patients prematurely die because of severe neurological disabilities, such as bulbar dysfunction and organic brain syndrome (3).

Two different genetic deficits are responsible for clinical variants of WS (type 1 and type 2 WS), with gastric or intestinal ulcers and excessive bleeding that are additional features in the type 2 form, while diabetes insipidus is absent.

Mutations in the WFS1 gene cause more than 90% of cases of classical type 1 WS (4), and they are responsible for the deficit of wolframin, the WFS1 gene product, which is located in the endoplasmic reticulum (ER) and regulates the intracellular calcium concentration: an adequate calcium balance is crucial for many different cellular functions, including cell-to-cell communication, muscle contraction, and protein processing. Wolframin has been found in different tissues, such as pancreas, brain, heart, muscles, lung, liver, kidney and bone (13), all potentially being affected in the WS because of the impairment of ER work driving cell apoptosis.

Case presentation

A 50-year-old Caucasian man was admitted in the Orthopedic Unit of our University Hospital because of tibia and fibula fractures of the right leg due to fall occurred at home (Figure 1). His medical history revealed a diagnosis of type 1 diabetes at the age of 4 year, treated with insulin combination (5), a slow and progressive loss of vision, deafness and consequently reduction of self-sufficiency; hypertension was diagnosed in the last 10 years. At admission, he had asthenia and alternated consciousness and stupor, without any neurological focal sign. A brain CT showed a reduction of the attenuation values of the periventricular white matter bilaterally and ample subarachnoid spaces and ventricular system above and below tentorial, the brain stem, the middle cerebellar peduncles and the worms have less volume than normal. Previously undiagnosed multiple rib fractures were documented at chest X-ray (Figure 2). At day 5 he underwent satisfactory surgical osteosyntesis by internal fixation.

Figure 1
Tibia and fibula fractures of the right leg in a patient affected by Wolfram syndrome.
Figure 2
Right rib fractures in a patient affected by Wolfram syndrome.

After surgery, at day 7 he was admitted in our Metabolic Unit for further investigations. Because of polyuria and excessive thirst, that were noted during hospitalization in spite of a good glycemic control and the absence of glycosuria, plasma and urine osmolality were measured (315 and 287 mOsm/KgH2O, respectively), confirming the suspicion of diabetes insipidus (6). The estimated glomerular filtration rate (eGFR) according to the CKD-EPI equation was 45 ml/min.

Due to the clinical features including early onset of diabetes mellitus, loss of vision due to optic atrophy and sensorineural hearing loss, but also sign of diabetes insipidus, the diagnosis of WS type 1 was hypothesized and then confirmed by the identification of a mutation in gene WFS1 encoding wolframin at DNA analysis (1, 4).

Because of multiple fractures, the patient also underwent a complete workout for osteoporosis. Bedside quantitative ultrasound (QUS) at the proximal phalangeal metaphysis of the last four fingers of the non-dominant hand (using a DBM Sonic Bone Profiler, Igea, Carpi, Italy) measured several parameters: Amplitude Dependent Speed of Sound (AD-SoS), Bone Transmission Time (BTT), Fast Wave Amplitude (FWA), Signal Dynamic (SDy), and, finally, Ultrasound Bone Profile Index (UBPI) was automatically calculated [UBPI= −(0.0018 × SDy − 0.0560 × FWA 0.0560 − 1.1467 × BTT + 3.0300)], which are presented in Table 1. Serum levels of surrogate markers of bone remodeling were determined, revealing a high bone turnover, with elevated levels of the bone resorption marker C-telopeptide of type 1 collagen (CTX) and the bone formation marker osteocalcin (BGP) (Table 1); moreover, a secondary hyperparathyroidism resulting from the combination of vitamin D deficit and incipient renal failure (eGFR: 45 ml/min) in addition to referred low dietary calcium intake was also observed (Table 1). All these exams indicated a reduced bone density and impaired bone metabolism consistent with severe osteoporosis with elevated bone turnover. Medical treatment for osteoporosis was then started with high dose of cholecalciferol (25000 UI/weekly) and calcium carbonate (500 mg/day), and programming the i.v. administration of zoledronic acid (5 mg/yearly) after the correction of secondary hyperparatiroidism. Treatment of diabetes insipidus with desmopressin nasal spray administration (5 μg twice a day) was also introduced during hospitalization. At day 16, after full recovery of consciousness and amelioration of clinical and laboratory parameters, the patient was then discharged. An insulin MDI regimen with insulin lispro and insulin glargine (40 UI/die) for the management of type 1 diabetes mellitus and valsartan 160 mg/die for the treatment of high blood pressure were confirmed at discharge.

Table 1
Phalangeal quantitative ultrasound (A), glucometabolic indices (B), bone metabolic parameters (C), and other laboratory data (D) of a patient affected by Wolfram syndrome with multiple fragility fractures.

Our work has been performed in accordance with ethical standards laid down in the 1964 Declaration of Helsinki. Informed consent was acquired from the patient for the use of his clinical data.

Discussion

WS is a very rare monogenic disease resulting from the combination of several medical disorders including diabetes mellitus, diabetes insipidus, optic atrophy, and hearing loss (1).

We reported the case of a man suffering from WS who incurred into multiple fractures because of a trivial fall. In order to explore bone health status, phalangeal QUS and several bone turnover markers, as well hormonal regulators of bone metabolism have been measured. In particular, phalangeal QUS measurements were previously associated with fractures and showed good association with DXA data (7); moreover phalangeal QUS may serve to evaluate bone quality that is, independently from DXA measurements, a determinant of bone strength (8, 9). QUS evaluation as well as clinical and laboratory data all indicated a reduced bone density and impaired bone metabolism consistent with severe osteoporosis with elevated bone turn-over in this patient.

Higher fracture rate was not previously reported in WF patients but, as WFS1 negatively regulates the ER stress response, and WFS1 deficiency in mice increases ER stress and triggers apoptosis, it may be speculated that apoptosis of bone cells could mediate bone fragility in WS (1, 10). WS clinical features progressively develop overtime, and the increased fracture risk may be a late manifestation of this rare syndrome. Thus, our patient was aged 50 years, and it has been described that WS patients usually die prematurely at the median age of 30 years (range 25–49 years) (3, 11), which could explain the lack of previous reports in the literature.

The alternate hypothesis is that fractures are related to the presence of type 1 diabetes mellitus per sé. The association of bone abnormalities with diabetes has been increasingly recognized (1215) and, irrespectively of age, subjects with type 1 diabetes show decreased value of bone mineral density (BMD) and increased fracture risk when compared with healthy age-matched controls (13, 14). Impairment of bone health is linked to insulin deficiency that has detrimental effects on bone biomechanical properties, leading to decreased strength and mineralized surface area, and also decreased osteoid surface (16, 17). Chronic hyperglycemia may increase PPARγ2 expression, thus suppressing osteoblast differentiation and promoting an adipocyte-like phenotype (18, 19); moreover it encourages non-enzymatic glycosylation of key proteins in bone, such as collagen type 1, and animals with high content of pentosidine, a glycation-induced non-enzymatic cross-link of collagen type 1, showed higher fracture risk, despite normal BMD (19, 20). Due to the early age of its onset, type 1 diabetes can result in failure to reach an adequate peak of bone mass, as possibly in the case of our patients, and impaired bone metabolism related to diabetes could maintain a lower BMD in comparison to healthy age- and sex- matched subjects (18). The role of some adipokines, as leptin, ghrelin and adiponectin, may also exert additional detrimental effects on bone in diabetic subjects (21, 22).

Also diabetes insipidus may contribute to the pathogenesis of impaired bone strength in WS. Thus, arginine vasopressin (AVP) was shown to stimulate renal production of PGE2 and PGF2a may be involved both in bone formation and in bone resorption (23), and a reduced urinary excretion of PGs was reported in subjects with diabetes insipidus (24); moreover, hyperactivation of the hypothalamus-pituitary-adrenal axis may increase cortisol secretion with consequent corticosteroid-related bone impairment (25).

Finally, the high risk of fall, due to vision deficit and neurological alterations observed in affected subjects (9, 13, 26), also boosts the possibility of fractures in WS.

The high bone turn-over rate observed in our patient, as resulted from high levels of BGP and serum CTX was consistent with the recent osteoporotic fractures, and possibly with prolonged immobilization (27). The low vitamin D levels and the decreased kidney function may also have contributed to the hyperparathyroidism with further perturbation of bone homeostasis and demineralization (28).

In conclusion, to the best of our knowledge, this is the first report of osteoporosis and fragility fractures in a patient affected by WS. Although no specific treatment of WS is currently available for this rare disease, screening for osteoporosis and fracture prevention should be required in order to improve quality of life in affected subjects.

References

1. Najjar SS, Saikaly MG, Zaytoun GM, Abdelnoor A. Association of diabetes insipidus, diabetes mellitus, optic atrophy, and deafness. The Wolfram or DIDMOAD syndrome. Arch Dis Child. 1985;60(9):823–828. [PMC free article] [PubMed]
2. Wolfram DJ, Wagener HP. Diabetes mellitus and simple optic atrophy among siblings: report of four cases. Mayo Clin Proc. 1938;1:715–718.
3. Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet. 1995;346(8988):1458–1463. [PubMed]
4. Aloi C, Salina A, Pasquali L, Lugani F, Perri K, Russo C, Tallone R, Ghiggeri GM, Lorini R, d’Annunzio G. Wolfram syndrome: new mutations, different phenotype. PLoS One. 2012;7(1):e29150. [PMC free article] [PubMed]
5. Cucinotta D, Russo GT. Biphasic insulin aspart in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2009;10(17):2905–2911. [PubMed]
6. Adam P. Evaluation and management of diabetes insipidus. Am Fam Physician. 1997;55(6):2146–2153. [PubMed]
7. Catalano A, Morabito N, Basile G, Fusco S, Castagna G, Reitano F, Albanese RC, Lasco A. Fracture risk assessment in postmenopausal women referred to an Italian center for osteoporosis: a single day experience in Messina. Clin Cases Miner Bone Metab. 2013;10(3):191–194. [PMC free article] [PubMed]
8. Catalano A, Morabito N, Agostino RM, Basile G, Gaudio A, Atteritano M, Natale G, Xourafa A, Morini E, Adamo V, Lasco A. Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors. Menopause. 2017;24(1):85–91. [PubMed]
9. Russo GT, Giandalia A, Romeo EL, Morabito N, Muscianisi M, Ruffo MC, Catalano A, Cucinotta D. Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences. Int J Endocrinol. 2016 doi: 10.1155/2016/1615735. [PMC free article] [PubMed] [Cross Ref]
10. Guo X, Shen S, Song S, He S, Cui Y, Xing G, Wang J, Yin Y, Fan L, He F, Zhang L. The E3 ligase Smurf1 regulates Wolfram syndrome protein stability at the endoplasmic reticulum. J Biol Chem. 2011;286(20):18037–18047. [PMC free article] [PubMed]
11. Urano F. Wolfram Syndrome: Diagnosis, Management, and Treatment. Curr Diab Rep. 2016;16(1):6. doi: 10.1007/s11892-015-0702-6. [PMC free article] [PubMed] [Cross Ref]
12. Schwartz AV. Diabetes mellitus: Does it affect bone? Calcif Tissue Int. 2003;73:515–519. [PubMed]
13. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007;22(9):1317–1328. [PubMed]
14. Catalano A, Morabito N, Di Vieste G, Pintaudi B, Cucinotta D, Lasco A, Di Benedetto A. Phalangeal quantitative ultrasound and metabolic control in pre-menopausal women with type 1 diabetes mellitus. J Endocrinol Invest. 2013;36(5):347–351. [PubMed]
15. Catalano A, Pintaudi B, Morabito N, Di Vieste G, Giunta L, Bruno ML, Cucinotta D, Lasco A, Di Benedetto A. Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus. Eur J Endocrinol. 2014;171(3):293–300. [PubMed]
16. Dixit PK, Ekstrom RA. Decreased breaking strength of diabetic rat bone and its improvement by insulin treatment. Calcif Tissue Int. 1980;32(3):195–199. [PubMed]
17. Goodman WG, Hori MT. Diminished bone formation in experimental diabetes. Relationship to osteoid maturation and mineralization. Diabetes. 1984;33(9):825–831. [PubMed]
18. McCabe LR. Understanding the pathology and mechanisms of type 1 diabetic bone loss. J Cell Biochem. 2007;102:1343–1357. [PubMed]
19. Giaccari A, Sorice G, Muscogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment. Nutr Metab Cardiovasc Dis. 2009;19(5):365–377. [PubMed]
20. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010;21:195–214. [PubMed]
21. Horcajada-Molteni MN, Chanteranne B, Lebecque P. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res. 2001;16(5):958–965. [PubMed]
22. Reid IR. Relationships between fat and bone. Osteoporos Int. 2008;19(5):595–606. [PubMed]
23. Kagaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res. 1995;313:36–46. [PubMed]
24. Bankir L, Trainh Trang Tan MM, Nivez MP, Sraer J, Ardaillou R. Altered PG production by glomeruli and papilla of rats with hereditary diabetes insipidus. Prostaglandins. 1990;20:349–365. [PubMed]
25. Mazza E, Goffi S, Barchi P, Arvat E, Bellone J, Limone P, Ghigo E, Camanni F. Enhanced adrenocorticotrophic hormone and cortisol response to corticotrophin-releasing hormone in central idiopathic diabetes insipidus. Eur J Endocrinol. 1994;130:121–124. [PubMed]
26. Piscitelli P1, Neglia C, Vigilanza A, Colao A. Diabetes and bone: biological and environmental factors. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):439–445. [PubMed]
27. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA. IOF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420. [PubMed]
28. Schipper LG, Fleuren HW, van den Bergh JP, Meinardi JR, Veldman BA, Kramers C. Treatment of osteoporosis in renal insufficiency. Clin Rheumatol. 2015 Aug;34(8):1341–1345. [PubMed]

Articles from Clinical Cases in Mineral and Bone Metabolism are provided here courtesy of CIC Edizioni Internazionali